TABLE 3.

Summary of the four female patients with metastatic breast cancers in pancreas diagnosed by FNA

Pt	Age (Y)	Location of pancreatic mass & size by imaging	Dx & biomarkers of primary tumor/metastasis	Treatment for primary tumor	Other metastatic sites	Interval of primary tumor and pancreatic metastasis	Follow‐up time from Dx of pancreatic metastasis
I	62	Head, 3.5 cm	IDC ER+, PR‐, HER2(3+) /Same	Lumpectomy Chemo XRT	Bone, liver, brain	21 Y	5.7 years (died)
II	37	Head, 2.4 cm	IDC Triple negative /Same	Neoadjuvant T‐mastectomy Whipple	Liver (s/p Whipple)	3.3 Y	2.8 years (died)
III	55	Head, 2.6 cm Body, 2.9 cm	IDC Triple negative /Same	Neoadjuvant Intended‐ Lumpectomy XRT	Bone, liver, brain	1 Y	1 month (died)
IV	64	Head, 3.7 cm	IDC ER‐, PR‐, HER2(3+) /Same	Chemo	Bone, liver, brain	Synchronous*	6 years (stable)

Abbreviations: Ca, carcinoma; Chemo, chemotherapy; Dx, diagnosis; Hx, history; IDC, Infiltrating ductal carcinoma; Neoadjuvant, neoadjuvant chemotherapy; Pt, Patient; T, total; XRT, radiotherapy; Y, year(s).

^*Breast mass found clinically on patient presentation.